跳至主要内容
临床试验/DRKS00033548
DRKS00033548已完成Unknown

Evaluation of gastric water emptying in fasted and fed state inyoung and advanced age populations with the use of a press-coated tablet containing caffeine - Saliva_AgePop_fasted&fed

Institut für Pharmazie, Abteilung Biopharmazie und Pharmazeutische Technologie0 个研究点目标入组 31 人开始时间: 2024年6月10日最近更新:
适应症

试验速览

阶段
Unknown
状态
已完成
发起方
入组人数
31

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • Subjects eligible for inclusion in this study arm have to fulfill all of the following criteria:
  • written informed consent (Einverständniserklärung”) ICF must be btained before any assessment is performed
  • sex: male or female
  • Study arm 1 and 2:
  • age: =65 years
  • body mass index: =18 kg/m² and = 30 kg/m²
  • Study arm 3:
  • body mass index: =18 kg/m² and = 35 kg/m²
  • intake of 5 or more medications
  • Study arm 4 and 5:
  • Age: =18 years and < 65 years

排除标准

  • Study arm 1, 2, 4, 5:
  • Subjects fulfilling any of the following criteria are not eligible for inclusion in this study:
  • Current participation in any clinical study including the use of any investigational drugs at the time of enrolment, or within 5 half-lives of enrolment, whichever is longer; or longer if required by local regulations
  • weight less than 45 kg
  • known allergic reactions or food intolerance to the tablets or meals ingredients
  • gastrointestinal diseases and/or pathological findings, which might interfere with gastrointestinal motility and emptying processes
  • gastrointestinal diseases and/or pathological findings, which pose a risk for intake of solid oral dosage forms (e.g. esophagus stents, esophagus varices, hiatal hernia)
  • diseases and/or pathological findings and/or respective treatments that do not allow the intake of a solid meal or solid oral dosage forms (e.g. dysphagia, diseases needing tube feeding)
  • drug or alcohol addiction
  • smokers of 10 or more cigarettes per day
  • eating disorders e.g. anorexia, bulimia
  • heavy tea or coffee drinkers (more than 1L per day)
  • subjects suspected or known not to follow instructions
  • subjects who are unable to understand the written and verbal instructions, regarding the risks and inconveniences they will be exposed to as a result of study participation
  • cognitive impairments that disable subjects to give informed consent (e.g. Alzheimer’s disease, Dementia)
  • medical history of orthostatic dysregulation, fainting, or blackouts
  • medical history of upper gastrointestinal surgical procedure
  • chemotherapy
  • less than 2 weeks after last acute disease
  • less than 1 week after last blood donation
  • therapy with transdermal patches
  • therapy with drugs that affect the gastrointestinal motility (The use of oral contraceptives is permitted in study arms 4 and 5)
  • therapy with drugs that alter gastric pH
  • Study arm 3:
  • Subjects fulfilling any of the following criteria are not eligible for inclusion in this study:
  • weight less than 45 kg
  • known allergic reactions or food intolerance to the tablets or meals ingredients
  • gastrointestinal diseases and/or pathological findings, which pose a risk for intake of solid oral dosage forms (e.g. esophagus stents, esophagus varices, hiatal hernia)
  • diseases and/or pathological findings that do not allow the intake of a solid meal or solid oral dosage forms (e.g. dysphagia, diseases needing tube feeding)
  • drug or alcohol addiction
  • heavy tea or coffee drinkers (more than 1L per day)
  • subjects suspected or known not to follow instructions
  • subjects who are unable to understand the written and verbal instructions, regarding the risks and inconveniences they will be exposed to as a result of study participation
  • cognitive impairments that disable subjects to give informed consent (e.g. Alzheimer’s disease, Dementia)

研究者

发起方
Institut für Pharmazie, Abteilung Biopharmazie und Pharmazeutische Technologie

相似试验